← Back to Search
Clinical And Metabolic Effects Of Different Doses Of Prostaglandin E1 In Man. Prostaglandin And Related Factors.
Published 1968 · Medicine
(PGE1) Prostaglandin E1 was infused intravenously into 8 healthy male subjects. The dose was successively increased to the maximal tolerable dose and varied from 0.032-0.58 mcg/kg/minute. When the lower doses were given there were either no clinical effects or only a flushing of the face. However when the dose was increased the flushing generally became more intensive and extended to other parts of the body mainly the arms and hands. In some of the subjects the flushing diminished and even changed to pallor with the highest doses of PGE1. All subjects complained of headache which usually became severe. In 1 subject the headache was unilateral and was accompanied by visual symptoms. All subjects developed cramps in the upper abdomen which generally become so severe that the administration of PGE1 had to be stopped. Several of the subjects also felt sore in other parts of the body such as the back and legs. The various symptoms disappeared within 15-30 minutes after the end of the infusion. The arterial levels of (FFA) free fatty acids in blood plasma increased in all subjects. In several cases the rise was discontinuous and in 2 of them a decrease in FFA level was seen. FFA response to PGE1 was neither related to administered doses nor to clinical effects. Turnover rate studies with labelled palmitic acid showed that the plasma FFA changes were mainly caused by variations in the rate of mobilizaton of FFA into the blood. The plasma levels of glycerol showed the same type of response to PGE1 as the FFA levels. No significant changes in blood glucose were seen in the subjects who were fasting. The 1 subject who had breakfast showed a rapid rise int he blood glucose concentration. (Authors modified)